Loading
Infusions of natural killer cells from donors or cord blood, sometimes fitted with a CAR, offering an off-the-shelf alternative to CAR-T with less cytokine release.
Natural killer cells kill cancer cells without prior sensitisation and do not cause graft-versus-host disease, so donor-derived, cord-blood or iPSC-derived NK products can be made off the shelf. CAR-NK cells against CD19 produced responses in lymphoma in early trials with little cytokine release syndrome or neurotoxicity, and cytokine-induced memory-like NK cells are tested in leukaemia. Limited persistence and expansion in patients remain the central problems.
NK cells from a donor, cord blood or a pluripotent stem cell line are expanded, optionally engineered with a CAR and interleukin-15, and infused after lymphodepletion.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"NK cell therapy and CAR-NK" OR ABSTRACT:"NK cell therapy and CAR-NK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NK cell therapy and CAR-NK, not a curated reading list.
Shares Cryopreservation and cell-therapy cold chain, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
Shares Cell-therapy release and potency testing, Cryopreservation and cell-therapy cold chain, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia.